Key result
Angiotensinogen -6A/G and -20A/C polymorphisms were not associated with blood pressure reductions following 8 weeks of telmisartan treatment in Chinese patients with hypertension (p>0.05).
Why the study?
This study aimed to investigate whether mononucleotide polymorphisms of the angiotensinogen gene at promoter were associated with the blood-pressure-lowering response to telmisartan treatment.
Are -6A/G and -20A/C polymorphisms of the angiotensinogen gene associated with the blood-pressure-lowering response to telmisartan in Chinese patients with hypertension?
Cohort (n=148)
Single-blind
Are -6A/G and -20A/C polymorphisms of the angiotensinogen gene associated with the blood-pressure-lowering response to telmisartan in Chinese patients with hypertension?
p-value: p=>0.05
Angiotensinogen gene promoter polymorphisms (-6A/G and -20A/C) do not significantly influence the antihypertensive response to telmisartan in Chinese patients.
These variants should not guide telmisartan selection; leaves open whether other genetic factors predict antihypertensive response.
INTRODUCTION:: This study aimed to investigate whether mononucleotide polymorphisms of the angiotensinogen gene at promoter were associated with the blood-pressure-lowering response to telmisartan treatment. MATERIALS AND METHODS:: After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day of telmisartan and then were followed up for eight weeks. The -6A/G and -20A/C polymorphisms of the angiotensinogen gene at promoter were determined through polymerase chain reaction and restriction fragment length polymorphsim analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after eight weeks of treatment. RESULTS:: There were no significant differences between -6A/G, -20A/C polymorphisms of the angiotensinogen gene and blood pressure reductions after treatment, p>0.05. CONCLUSION:: It is suggested that angiotensinogen-6 A/G and angiotensinogen-20 A/C polymorphisms were not associated with the antihypertensive response to telmisartan treatment in Chinese patients with hypertension.
No takes yet. Share an insight, caveat, or question.
Gong et al. (2019) conducted a cohort in mild-to-moderate primary hypertension (n=148). Angiotensinogen gene -6A/G and -20A/C polymorphisms was evaluated on blood pressure reductions after treatment (p=>0.05). Angiotensinogen -6A/G and -20A/C polymorphisms were not associated with blood pressure reductions following 8 weeks of telmisartan treatment in Chinese patients with hypertension (p>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: